C 6822

Drug Profile

C 6822

Latest Information Update: 13 Apr 1995

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Eli Lilly; Millennium Pharmaceuticals
  • Class Ischaemic heart disorder therapies; Peptides
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 12 Apr 1995 Discontinued-Preclinical for Myocardial infarction in USA (Unknown route)
  • 12 Apr 1995 Discontinued-Preclinical for Stroke in USA (Unknown route)
  • 12 Apr 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top